NBIX NEUROCRINE BIOSCIENCES INC Insider Trading

CSO Jude Onyia sold 11,000 NBIX shares at $160.25 (scheduled 10b5-1 plan, retains 13,268 options)

Chief Scientific Officer Jude Onyia sold 11,000 shares at $160.25 on 2026-06-01, reducing non-derivative holdings by 29.9% from 36,846 to 25,846 shares, with a total transaction value of $1,762,710.40. This sale is part of a pre-arranged 10b5-1 trading plan adopted on 2026-02-25, meaning the transaction was scheduled rather than discretionary. The stock's current price of $154.84 sits 4.6% below its 52-week high of $162.39, and the company reports strong fundamentals with net income of $197,900,000.00 on revenue of $814,500,000.00 and annual revenue growth of +21.4%. The insider retains 13,268 non-qualified stock options, maintaining a material position in the company. His prior two sales at NBIX showed mixed outcomes: a -4.2% 30-day return and a -0.9% 30-day return, though 90-day returns were positive at +5.0% and +7.9% respectively.

NBIX Chief Scientific Officer Jude Onyia sells 11,000 shares at $155.53 via pre-arranged 10b5-1 plan; retains 25,846 shares plus 24,268 options.

Jude Onyia, Chief Scientific Officer, executed a scheduled sale of 11,000 shares for $1,710,865.20 under a pre-arranged 10b5-1 trading plan adopted on 2026-02-25, reducing non-derivative holdings by 29.9% from 36,846 to 25,846 shares while retaining 24,268 non-qualified stock options. The sale occurred at $155.53, which is 2.5% below the 52-week high of $162.39, as the stock has risen 20.6% over the past 30 days and 19.7% over 90 days. His prior two sales at NBIX showed mixed outcomes: the 2025-07-09 sale saw 30-day returns of -4.2% but 90-day returns of +5.0%, while the 2025-07-02 sale had 30-day returns of -0.9% and 90-day returns of +7.9%. Because this sale is scheduled rather than discretionary, price timing cannot be inferred as a signal of insider conviction. With NBIX fundamentals showing $814.5M in latest quarterly revenue, $197.9M net income, and 21.4% annual revenue growth, the transaction reflects a routine vest-and-sell within a pre-approved framework.

Director Kevin Charles Gorman sold 245,088 shares of NBIX at $154.33 for $37.8M under 10b5-1 plan; retains 511,293 shares.

Director Kevin Charles Gorman executed a scheduled sale of 245,088 shares at $154.33 on 2026-05-19 under a pre-arranged 10b5-1 trading plan adopted on 2026-02-17, reducing his holdings to 511,293 shares from 756,381 shares. His prior five trades at NBIX show mixed near-term outcomes: three measurable sales posted 30-day returns of +14.0%, +5.3%, and -21.3%, while his cross-ticker track record across all tickers shows 8 prior sells with an average 90-day return of +1.4%. NBIX fundamentals remain solid with annual revenue growth of +21.4%, net income of $197,900,000.00, and a P/E of 23.38, though the stock currently trades at $155.50, down -4.2% from the 52-week high of $162.39. This is a scheduled, non-discretionary transaction, so timing characterization is not applicable.

Director Richard Pops sold 15,000 NBIX shares at $157.65 for $2.4M via pre-arranged 10b5-1 plan on 2026-05-15.

Richard F Pops sold 15,000 shares (30.3% of his pre-transaction holdings of 49.5K shares) at $157.65, leaving him with 34.5K shares post-transaction. This sale was executed under a pre-arranged 10b5-1 trading plan, meaning it was scheduled rather than discretionary. The company's fundamentals remain solid with revenue of $814.5M (annual growth +21.4%) and net income of $197.9M, supporting a current valuation of $15.8B market cap at a P/E of 23.64. The stock has appreciated 18.0% over the past 30 days and 23.0% over 90 days, trading at $157.21 currently, near its 52-week high of $162.39. As a scheduled transaction under a 10b5-1 plan, this sale carries no timing signal and should be evaluated solely as a change in the director's residual position from 49.5K to 34.5K shares.